SAT0231 Safety of Subcutaneous Belimumab in Patients With Systemic Lupus Erythematosus: A 6-Month Open-Label Extension Study

doi 10.1136/annrheumdis-2017-eular.5235
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Belimumab in Systemic Lupus Erythematosus

RMD Open
RheumatologyAllergyImmunology
2015English

Psy62 - Direct Cost Offsets Related to Belimumab Subcutaneous Administration in Patients With Systemic Lupus Erythematosus in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Experience of Long-Term Belimumab Use in Patients With Systemic Lupus Erythematosus (A Case Report)

Modern Rheumatology Journal
2013English

Belimumab in Systemic Lupus Erythematosus: An Update for Clinicians

Therapeutic Advances in Chronic Disease
Medicine
2011English

Response to Belimumab Among Patients With Systemic Lupus Erythematosus in Clinical Practice Settings: 24-Month Results From the OBSErve Study in the USA

Lupus Science and Medicine
MedicineImmunology
2016English

Tuberculosis in Patients With Systemic Lupus Erythematosus.

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1982English

Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of the Phase 3 United States BLISS-76 Trial

Arthritis and Rheumatology
RheumatologyAllergyImmunology
2018English

Increased Risk of Depression in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus: A Danish Nationwide Cohort Study

British Journal of Dermatology
DermatologyMedicine
2018English

Bone Health in Patients With Systemic Lupus Erythematosus

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy